Status: Recruiting
Single Ascending and Multiple Ascending Dose Study of LCA-0061
This is a Phase 1combined single ascending dose (SAD)/multiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).
Participants needed: 72
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Lycia Therapeutics, Inc.Updated: Jul 14, 2026Locations: 1
Eligibility criteria
Must provide written consent for participation [+6]
Pregnant or lactating [+16]